Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PGN-EDODM1 in Myotonic Dystrophy Type 1
NCT06204809Phase 1Completed
- Sponsor
- PepGen
- Start
- Dec 2023
- Primary completion
- Oct 2025
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 3
01
Overview
Phase 1, randomised, double-blind trial in myotonic dystrophy type 1 (DM1) comparing PGN-EDODM1 with Placebo (2 arms). Primary endpoint: Number of participants with Adverse Events at 16 weeks. Started Dec 2023; status: completed.
02
Drugs
PGN-EDODM1
03
Conditions
myotonic dystrophy type 1 (DM1)
Beyond the preview
Go deeper on NCT06204809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06204809.